Kornimate/medical-research-clean huggingface dataset:
behavioral and biomedical hiv prevention interventions for thai men who have sex with men

Conditions: HIV Testing, MSM

Summary: objectives 1. to evaluate the acceptability and feasibility of "standard hiv prevention package" among thai men who have sex with men (msm) 2. to conduct a pilot study to demonstrate the acceptability and feasibility of internet-based social networking, asymptomatic sexually transmitted infection diagnosis and treatment and pre-exposure prophylaxis strategies as "potential hiv prevention methods" among thai msm 3. to use mathematical modeling to identify the most effective hiv prevention package optimized for thai msm subject population: hiv-negative msm clients of the thai red cross anonymous clinic (trc-ac), age ≥18 years old,each participant will have a 12-month follow-up duration in the study.

study design and methodology: we will conduct a pilot study among 100 msm participants who will be enrolled from the trc-ac and will be followed up for 12 months. participants will be followed at baseline, months 1 and 3, and then every 3 months. interventions in the "standard hiv prevention package" to be provided at every clinic visit include anti-hiv testing, risk reduction counseling, provisions of free condoms and lubricants and diagnosis and treatment of symptomatic sexually transmitted infections (sti). all participants will also have access to non-occupational post-exposure prophylaxis (npep) without charge as part of the standard hiv prevention package. in addition, we will test for acceptability and feasibility of the "potential hiv prevention methods" which include: 1) internet-based social networking to distribute and stimulate discussion of hiv prevention information (2) asymptomatic sti diagnosis and treatment for every participant at baseline visit and every 6 months (3) oral and topical pre-exposure prophylaxis (prep) strategies using placebo tablet and gel. the meta-analysis of various behavioral and biomedical hiv prevention studies among msm will be done in parallel with the pilot study in order to gather information for mathematical modeling and finally to inform the design of a larger study. data acquired from the pilot study will be used for mathematical modeling of hiv transmission among msm. the output from the modeling will directly inform hiv preventative interventions to be evaluated empirically among msm in thailand.

Eligibility criteria:
inclusion criteria: 1. age 18 years old or older 2. have documented negative hiv eia or cmia test at screening 3. live in or near bangkok 4. have a history of anal sex with men 5. understand the study and sign informed consent form. exclusion criteria: 1. persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with ability to give informed consent 2. persons with history of urinary tract stone

Keywords: 100 hiv-negagtve msm
ak135 in patients with chemotherapy-induced peripheral neuropathy (cipn)

Conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN)

Summary: a phase i open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of ak135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with malignant tumor


Eligibility criteria:
inclusion criteria: 1. written and signed informed consent. 2. eastern cooperative oncology group (ecog) performance score of 0 or 1. 3. life expectancy ≥ 3 months. 4. histologically or cytologically documented malignant tumor. 5. previous anti-tumor therapy causing peripheral neurotoxicity that has been discontinued for at least 1 month before enrollment. 6. diagnosed with chemotherapy-induced peripheral neuropathy (cipn) by an oncologist or neurologist, with at least grade 2 nci common terminology criteria for adverse events. 7. must have pain and/or numbness due to chemotherapy-induced peripheral neuropathy (cipn) symptoms. 8. adequate organ function. exclusion criteria: 1. pharmacologic or non-pharmacologic treatment for cipn within 2 weeks before the first dose of ak135. 2. concurrent and/or scheduled to start any anti-tumor treatment that may cause chemotherapy-induced peripheral neuropathy (cipn) within 3 months after the first dose of ak135. 3. concurrent and/or scheduled to start any anti-tumor treatment that may cause hand-foot skin reaction within 3 months after the first dose of ak135. 4. presence with other illnesses may result in peripheral neuropathy including, autoimmune diseases, diabetes and metabolic syndrome, peripheral vascular disease, infections, nerve injury or compression, vitamin deficiencies, and so on. 5. skin lesions may affect the assessment of peripheral neuropathy. 6. unresolved toxicities from prior anti-cancer therapy within 2 weeks before the first dose of ak135, defined as not having resolved to nci ctcae v5.0 grade 0 or 1, or levels specified in the inclusion/exclusion criteria, except for alopecia, and neuropathy. 7. known allergy or reaction to any component of the ak135 formulation. history of severe hypersensitivity reactions to other mabs.
multimodal assessment of knee conditions in rehabilitation

Conditions: ACL Injury

Summary: the purpose of this study is to assess acl injury and other pathological knee conditions from the combination of signals that are known to provide information on the knee joint.


Eligibility criteria:
inclusion criteria: * acl injury * ages 18-40 * female exclusion criteria: * bmi under 18 * bmi over 40 * contraindications to mri

Keywords: osteoarthritis acl injury knee trauma meniscus tear
a study to evaluate the efficacy and safety of eplerenone in the treatment of hypertension in children.

Conditions: Hypertension

Summary: to evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. the study will last approximately 10 weeks and about 320 patients will participate.


Eligibility criteria:
inclusion criteria: * 6-16 years old male and female * systolic blood pressure greater than or equal to the 95th percentile for age, gender, and height, measured on at least 3 separate occasions exclusion criteria: * k/doqi classification of stages of chronic kidney disease equal to or greater than 3 * serum or whole blood potassium \> 5.5 meq/l
a study to assess luspatercept in lower-risk myelodysplastic syndrome participants

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to evaluate the efficacy and safety of luspatercept when administered at the maximum approved dose in low-risk myelodysplastic syndrome participants who require red blood cell transfusions.


Eligibility criteria:
inclusion criteria: * participant had documented diagnosis of mds according to world health organization (who) classification that met revised international prognostic scoring system (ipss-r) classification of very low-, low-, or intermediate-risk disease. * participant has an eastern cooperative oncology group (ecog) score of 0, 1, or 2. * participant must have red blood cell transfusions according to study criteria. exclusion criteria: * participant has known clinically significant anemia due to iron, vitamin b12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding. * participant has had a prior allogeneic or autologous stem cell transplant. * participant has known history or diagnosis of aml. * participant has uncontrolled hypertension. other protocol-defined inclusion/exclusion criteria apply

Keywords: luspatercept transfusion dependent ace-536 anemia blood transfusion red blood cell transfusion myelodysplastic syndrome
rhapsody: diagnostic utility of rush following rosc

Conditions: Cardiac Arrest

Summary: this will be a prospective observational study of adult primary cardiac arrest patients presenting to shands emergency department following rosc or actively in cardiac arrest with subsequent rosc after treatment in the emergency department.

this will be a prospective observational study of adult primary cardiac arrest patients presenting to shands emergency department following rosc or actively in cardiac arrest with subsequent rosc after treatment in the emergency department. the study will be a single center pilot study to evaluate the role of the extended rush exam in patients following cardiac arrest in order to potentially diagnose the cause of their arrest. no control group will be included in this study due to ethical concerns of withholding a potentially life-saving diagnostic test. patients will be treated with acls per standard of care and resuscitation measures given. within two hours of return of spontaneous circulation, the rush exam will be performed by ultrasound-trained emergency department physicians with images saved into the qpath system, our already existing database where all emergency ultrasound exams - education and diagnostic - are stored currently. the physician who performed the exam will fill out a checklist with their interpretation and findings based on the elements included in the exam. the data collected will be stored in a redcap database. identifying data will be removed from the images and reviewed by two experienced ultrasonographers who will give separate interpretations, and inter-observer reliability will be examined. we will then correlate the interpretation with that of the physicians performing the exam. the elements of the rush exam that will be performed include focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for dvt and ocular ultrasound. the evaluation for dvt will be an abbreviated exam with one view of each of the bilateral femoral veins and popliteal veins. techniques for performing the exam are based on the 2012 rush guidelines \[2\]. the data will undergo statistical analysis to determine if the data supported the initial hypotheses. subjects will be contacted 30 days following the initial study for telephone follow-up and a cpc assessment for neurologic recovery will also be performed at that time.

Eligibility criteria:
inclusion criteria: * incoming er patients with return of spontaneous circulation after cardiac arrest exclusion criteria: * patients who do not achieve return of spontaneous circulation long enough for the exam to be performed * patients who have initial cardiac arrest while on an inpatient unit of the hospital

Keywords: spontaneous circulation (rosc) shock and hypotension (rush) exam
preoperative pain control in gastric bypass surgery patients

Conditions: Post-operative Pain

Summary: randomized clinical trial to evaluate whether a single pre-operative dose of pregabalin will alleviate post-operative pain and decrease post-operative analgesic requirements in morbidly obese patients undergoing laparoscopic gastric bypass surgery.

pregabalin is a popular adjunct for relieving neuropathic pain in diabetics. there have been multiple studies evaluating its use in pre and post-operative pain control in various surgeries. post-operative pain control is a challenging problem in bariatric patients due to the high doses of narcotic required, related to the high body mass, and the danger of concomitant respiratory depression. in the obese patient, the goal of postoperative pain management is provision of comfort, early mobilization and improved respiratory function, without causing inadequate pain control, respiratory compromise or increased nausea. methods: a randomized controlled trial, whereby patients undergoing laparoscopic roux-en-y gastric bypass will be administered a single pre-operative dose of pregabalin or a placebo. we plan to follow their immediate post-operative course in the hospital, with regard to the following primary endpoints: * post-operative analgesic requirements * post-operative pain scale (rated 0-10) * episodes of vomiting * post-operative antiemetic requirement * length of stay

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic roux-en-y gastric bypass surgery. exclusion criteria: -
an educational intervention to promote safe driving

Conditions: Driver Sleepiness

Summary: the general aim of the study is to promote safe, economic, and environmental-friendly driving among long-haul truck drivers. to do this, the investigators will conduct an on-road study on i) the relationship of driver sleepiness and stress with driving behaviour and fuel consumption and ii) effectiveness of an educational intervention in mitigating sleepiness at the wheel. the educational intervention is designed to be employed by occupational health care professionals in the future. this solution clearly facilitates the implementation of the intervention into practice if it turns out to be effective. the investigators specified research questions are the following: * do truck driver sleepiness and stress at the wheel reach levels that affect driving behaviour, fuel consumption and carbon emissions? * what are the sources of sub-optimal arousal at the wheel in truck drivers? * can truck driver sleepiness be mitigated by an educational intervention, and if yes, does it improve driving behaviour and decrease fuel consumption and carbon emissions as well?


Eligibility criteria:
inclusion criteria: * working as a truck driver at the moment of the study * having both day and night trips * having at least 2 years of experience in truck driving exclusion criteria: * not fluent in finnish (the intervention is in finnish)

Keywords: professional drivers sleepiness stress safe driving training
trial of new dietary treatment of diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this is a preliminary trial of a new dietary approach to the treatment of obesity related type 2 diabetes. study terminated december 19, 2005 for administrative reasons.

traditional dietary treatment of type 2 diabetes is complicated and often fails. this is a dietary treatment that uses fingerstick testing of blood sugars and a remarkably simple algorithm to promptly lower the blood glucose to treatment goals. a series of 10 overweight type 2 diabetic patients not well controlled, or needing medication for control, will be recruited to follow this plan; followup is to be until 6 months after the last patient is enrolled, or when all patients have normal a1cs with no medication, whichever comes first. primary endpoints to be measured are a1c, weight loss (in pounds and bmi reduction) and medication reduction. secondary endpoints are occurrences of hypoglycemia, reduction of medications for hypertension and hyperlipidemia, and patient satisfaction. as this is a phase 1 trial, the only control group is historical controls (the patients themselves and the medical literature).

Eligibility criteria:
inclusion criteria: * diabetes mellitus, type 2 * obesity * ability to attend office visits in manassas, virginia exclusion criteria: * dementia * institutionalized living * retinopathy, neuropathy * pregnancy * serious health problems such as heart disease or stroke

Keywords: obesity dietary treatment fasting as medical therapy
neoadjuvant concurrent chemoradiation with weekly docetaxel/cisplatin for resectable iiia-n2 nsclc

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study was to evaluate the safety and efficacy of neoadjuvant concurrent chemoradiation with weekly docetaxel/cisplatin in patients with resectable iiia-n2 nsclc.


Eligibility criteria:
inclusion criteria: * patients aged 18 years older. * present with histologically proven or cytological diagnosis of nsclc stage iiia as defined by the american joint committee on cancer staging criteria for lung cancer, that is amenable to surgery. * no prior systemic chemotherapy or targeted therapy for lung cancer before screening. * ecog performance status of 0 or 1. * life expectancy ≥12 weeks. * adequate hematological function:absolute neutrophil count (anc) ≥1.5 x 109/l, and platelet count ≥100 x 109/l, and hemoglobin ≥9 g/dl (may be transfused to maintain or exceed this level). * adequate liver function: total bilirubin ≤ 1.5 x upper limit of normal (uln);aspartate aminotransferase (ast), alanine aminotransferase (alt) ≤ 2.5 x uln in subjects without liver metastases; ≤ 5 x uln in subjects with liver metastases. * adequate renal function:serum creatinine ≤ 1.25 x uln, and creatinine clearance ≥ 60 ml/min. * female subjects should not be pregnant or breast-feeding. exclusion criteria: * patients with prior exposure to agents directed at the her axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab). * patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy). * history of another malignancy in the last 5 years with the exception of the following:other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted; cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted. * any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). * known hypersensitivity to tarceva or gemcitabine or cisplatin. * eye inflammation or eye infection not fully treated or conditions predisposing the subject to this. * evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.

Keywords: lung cancer
laparoscopic sleeve gastrectomy with endoscopic visualization

Conditions: Morbid Obesity

Summary: the main objective of this trial is to evaluate endoscopic visualization during a laparoscopic sleeve gastrectomy (lsg) procedure using an endoscope inserted transvaginally through a new device called a steerable flex trocar (sft).


Eligibility criteria:
inclusion criteria women will be enrolled in this study who: * are willing to give consent and comply with evaluation and treatment schedule; * are 21 to 60 years of age (inclusive), post menopausal, or otherwise no longer expect to bear children, e.g., previous tubal ligation; * are a candidate for surgical weight loss intervention (meets asmbs and nih criteria); * have no significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and/or behavioral recommendations; * agree to refrain from any type of elective procedures that would affect body weight such as abdominal lipoplasty or liposuction, mammoplasty, or removal of excess skin for the duration of the trial; * are american society of anesthesiologists (asa) class i, ii, or iii); and * have a negative pregnancy test (for women of childbearing potential). exclusion criteria subjects will be excluded from the study for any of the following: * previous pelvic surgery other than transverse c-sections and/or tubal ligation; * enlarged uterus; * evidence of pelvic malignancy on a screening ultrasound; * documented history of drug and/or alcohol abuse within 2 years of the screening visit; * previous malabsorptive or restrictive procedures performed for the treatment of obesity; * unable or unwilling to attend follow-up visits and examinations; * planned or predicted concurrent surgical procedure; * any medical condition which precludes compliance with the study; * immunocompromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders; * conditions that, in the opinion of the investigator, may jeopardize the subject's well-being and/or the soundness of this clinical study; * history or presence of pre-existing autoimmune connective tissue disease, e.g., systemic lupus erythematosus or scleroderma; * use of prescription or over the counter weight reduction medications or supplements, participation in weight-loss programs, or change in smoking habits within 8 weeks of the screening visit and for the duration of study participation; * participation in another clinical trial within 8 weeks of the screening visit and for the duration of this trial (unless previously approved by the investigator and sponsor); or * any condition which precludes compliance with the study (investigator discretion).

Keywords: obesity weight loss
hospital without dyspnea. rationale and design of a multidisciplinary intervention

Conditions: Dyspnea

Summary: dyspnea is a symptom that is growing in incidence, as respiratory and heart diseases are becoming more frequent. patients suffering from dyspnea have a significant disabling due to chronic refractory dyspnea and crisis of irruptive dyspnea. although there are several tools that may produce an improvement of symptom intensity, they are underused.

we sought to investigate whether if teaching interventions specifically addressed to medical staff improve the well-being of dyspneic patients. the main goal of this study is to evaluate the effect of two talks (conveyed to doctors and nurses of cardiology and respiratory medicine departments) on the patient-perceived dyspnea. the contents of these talks will be prepared and supervised by palliative care specialists. this is a four-staged study that includes a first observational phase (prevalence study of dyspnea) followed by intervention and a third phase that will determine the effect of this teaching intervention. the fourth phase consists in the elaboration of specific protocols for management of dyspnea. a pharmacovigilance study of opioids will also take place.

Eligibility criteria:
inclusion criteria: * hospital admission with dyspnea as main symptom * acceptance of participation in the study * diagnosis of chronic respiratory disease * diagnosis of chronic heart failure * chronic refractory dyspnea higher than 1/10 and irruptive dyspnea higher than 2/10 degree by rating numerical scale exclusion criteria: * cognitive impairment * voluntary dropout.

Keywords: dyspnea palliative care heart failure chronic pulmonary disease opioids
early prevention strategies of severe proliferative vitreoretinopathy base on precision diagnosis of single cell sequencingvitreoretinopathy

Conditions: Rhegmatogenous Retinal Detachment

Summary: study of initiating proliferative vitreoretinopathy (pvr)cell subtype (pvr initiating cells (pvr-ic) in rpe cells of rhegmatogenous retinal detachment (rrd) patients; to prove the percentage of pvr-ic decides the risk of serious pvr occurring after surgery; to investigate the safety and efficacy of early local steroids drug intervention in patients with severe postoperative pvr.


Eligibility criteria:
inclusion criteria: * (1) age: 18-60 years old, regardless of gender; (2) clinical diagnosis of with rhegmatogenic retinal detachment (rrd); (3) surgery for retinal detachment is required; (4) myopia \< = 800 degrees; (4) pvr classification: no restrictions; (5) patients undergoing the first or second operation. (6) patients volunteered to participate in this study and signed informed consent. exclusion criteria: * (1) exudative detachment of retina; (2) those who are allergic to the drugs used in the study; (3) combined with other eye diseases: other fundus diseases, glaucoma, corneal opacity diseases, genetic diseases); (4) history of internal eye surgery \>=3 times; (5) postoperative follow-up could not be scheduled; (6) patients with systemic diseases (such as asthma, heart failure, myocardial infarction, liver failure, kidney failure and other major diseases).